* If you want to update the article please login/register
We wanted to see if baseline metabolic tumor burden and therapy-response assessment by [18F]FDG PET/CT have a prognostic role in patients with metastatic melanoma receiving BRAF MEK inhibitors, which was [18F]MYK inhibitors. Patients undergoing a CMR were rewarded with a prolonged PFS than those with PMR. Conclusions Baseline TMTV and metabolic response can be useful prognostic tools for PFS and OS in patients with advanced melanoma treated with BRAF/MEK inhibitors. A TMTV > 56 cm 3 at baseline [ 18 F]FDG PET/CT was highly correlated with a shorter PFS and OS in a retrospective cohort of 57 metastatic melanoma patients treated with BRAF/MEK inhibitors, a TMTV > 56 cm 3 at baseline [ 18 F]FDG PET/CT was significantly related to a shorter PFS and OS in a retrospective cohort of 57 metastatic mela • The combination of baseline TMTV and PET response during therapy allowed for the identification of three groups of patients with very different median OS.
Source link: https://doi.org/10.1007/s00330-021-08355-1
Purpose: Objectives: To produce quantitative molecular imaging biomarkers of immune-related adverse event formation in malignant melanoma patients receiving immune-checkpoint inhibitors photographed with 18F-FDG PET/CT. Methods 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively assessed for signs of irAE, according to the authors' methods. Patients were compared to determine which patients had irAE, irAE grade, and time to irAE diagnosis. To measure irAE detection results, a region under the receiver-operating characteristic curve was used. Normal ranges for the SUV percentiles without irAE were bowel [1. 74, 2. 86 g/mL], lung [0. 73, 1. 46 g/mL], and thyroid [0. 86, 1. 99 g/mL]. Conclusions & Conclusions (irAE) Increased 18F-FDG uptake in irAE-affected organs provides predictive data about the onset of irAE in MM patients receiving ICI and can serve as a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical signs appear.
Source link: https://doi.org/10.1007/s00259-021-05650-3
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions